Impact of CYP2C9 genotype on pharmacokinetics:: Are all NSAIDs the same? -: Reply

被引：0
|
作者：
Pilotto, Alberto [1 ]
Franceschi, Marilisa
Scarcelli, Carlo
Niro, Valeria
Seripa, Davide
Colaizzo, Donatella
Grandone, Elvira
Andrjulli, Angelo
Dallapiccola, Bruno
Di Mario, Francesco
Leandro, Gioacchino
机构：
[1] IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Geriatr Unit, San Giovanni Rotondo, Italy
[2] IRCCS Casa Sollievo Sofferenza, Dept Res, Lab Gerontol & Geriatr, San Giovanni Rotondo, Italy
[3] Univ Parma, Dept Gastroenterol, I-43100 Parma, Italy
[4] IRCCS Casa Sollievo Sofferenza, Dept Res, Lab Atherosclerosis & Thrombosis, San Giovanni Rotondo, Italy
[5] IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Gastroenterol Unit, San Giovanni Rotondo, Italy
[6] CSS Mendel Inst, Rome, Italy
[7] IRCCS Saverio De Bellis, Gastroenterol Unit, Castellana Grotte, Italy
来源：
GASTROENTEROLOGY | 2007年 / 133卷 / 06期
关键词：
D O I：
10.1053/j.gastro.2007.10.020
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：2074 / 2075
页数：2
相关论文
共 50 条
  • [1] Impact of CYP2C9 genotype on pharmacokinetics:: Are all NSAIDs the same?
    van Oijen, Martijn G. H.
    Laheij, Robert J. E.
    GASTROENTEROLOGY, 2007, 133 (06) : 2073 - 2074
  • [2] Impact of CYP2C9 genotype on pharmacokinetics:: Are all cyclooxygenase inhibitors the same?
    Rodrigues, AD
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) : 1567 - 1575
  • [3] Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs
    Suarez-Kurtz, Guilherme
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (08): : 406 - 407
  • [4] Comparison of the impact of the CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of the NSAIDS celecoxib, diclofenac, and ibuprofen.
    Kirchheiner, J
    Meineke, I
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P75 - P75
  • [5] NSAIDS, CYP2C9 GENOTYPE, AND BREAST CANCER RISK
    Trentham-Dietz, A.
    Newcomb, P. A.
    Hampton, J. M.
    Kuan, L-Y
    Gould, M. N.
    Makar, K. W.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 169 : S136 - S136
  • [6] CYP2C9 Genotype-DependentWarfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R-and S-Warfarin and Their Oxidative Metabolites
    Flora, Darcy R.
    Rettie, Allan E.
    Brundage, Richard C.
    Tracy, Timothy S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (03): : 382 - 393
  • [7] Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam
    Perini, Jamila A.
    Suarez-Kurtz, Guilherme
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (05) : 549 - 551
  • [8] Influence of the CYP2C9 genotype on pharmacokinetics and COXI/II-inhibition properties of NSAIDs.
    Kirchheiner, J
    Meineke, I
    Roots, I
    Brockmöller, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (07) : S100 - S100
  • [9] NSAIDs: CYP2C9 genotype not related to risk of gastric ulcers
    Reactions Weekly, 2001, 870 (1) : 6 - 6
  • [10] Effect of CYP2C9 genotype on the pharmacokinetics of celecoxib.
    Gelmann, A
    Tang, C
    Rodrigues, AD
    Schwartz, JI
    Rushmore, T
    Waldman, SA
    Greenberg, HE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P27 - P27
12345